Does Rallies show Form 4 insider transactions for SGHT?

Yes. Rallies tracks SGHT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SGHT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SGHT. It does not provide personalized investment advice.

SGHT (Sight Sciences, Inc. Common Stock) Stock Analysis - Insider Trades

Sight Sciences, Inc. Common Stock (SGHT) is a publicly traded Healthcare sector company. As of May 21, 2026, SGHT trades at $4.86 with a market cap of $264.43M and a P/E ratio of -6.45. SGHT moved +2.75% today. Year to date, SGHT is -36.97%; over the trailing twelve months it is +48.62%. Its 52-week range spans $2.03 to $9.24. Analyst consensus is buy with an average price target of $8.73. Rallies surfaces SGHT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SGHT stock inside the company?

Recent SGHT insider activity includes Rodberg James sold 7.23K, HAYDEN JEREMY B. sold 13.76K, Bauerlein Alison sold 25.87K, Badawi David sold 8.17K, and Taylor Brenton sold 2.87K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SGHT Key Metrics

Key financial metrics for SGHT
Metric	Value
Price	$4.86
Market Cap	$264.43M
P/E Ratio	-6.45
EPS	$-0.74
Dividend Yield	0.00%
52-Week High	$9.24
52-Week Low	$2.03
Volume	0
Avg Volume	0
Revenue (TTM)	$77.36M
Net Income	$-38.43M
Gross Margin	86.17%

Recent SGHT Insider Trades

Rodberg James sold 7.23K (~$25.67K) on Apr 6, 2026.
HAYDEN JEREMY B. sold 13.76K (~$48.85K) on Apr 6, 2026.
Bauerlein Alison sold 25.87K (~$90.04K) on Apr 2, 2026.
Badawi David sold 8.17K (~$28.42K) on Apr 2, 2026.
Taylor Brenton sold 2.87K (~$10.62K) on Apr 1, 2026.

Latest SGHT News

Sight Sciences Cuts Emissions by Over 20% and Funds 24 Indigent Care Programs — Apr 22, 2026
Sight Sciences Highlights OMNI IOP Control and TearCare Superiority at ASCRS 2026 — Apr 1, 2026
Sight Sciences Q4 interventional dry eye revenue rises 133% to $0.7M — Mar 5, 2026
Sight Sciences Q4 EPS Loss of $0.08 Beats Estimate, Revenue $20.4M — Mar 4, 2026

SGHT Analyst Consensus

8 analysts cover SGHT: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.73.

Common questions about SGHT

Who is trading SGHT stock inside the company?: Recent SGHT insider activity includes Rodberg James sold 7.23K, HAYDEN JEREMY B. sold 13.76K, Bauerlein Alison sold 25.87K, Badawi David sold 8.17K, and Taylor Brenton sold 2.87K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SGHT?: Yes. Rallies tracks SGHT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SGHT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SGHT. It does not provide personalized investment advice.